DT2216 leads to cell growth suppression in an SET2 AML model in vivo. (A) Bioluminescent images of mice transplanted with SET2 leukemia cells. Mice were administered vehicle or DT2216 twice a week from day 7 to day 35 after transplantation. The same mice are depicted at each time point (n = 4 mice per group). (B) Quantification of bioluminescence emitted from the whole body of each mouse described in panel A at the indicated time points. The P values were determined using the t test (∗P < .05; ∗∗P < .01). (C) Kaplan-Meier survival curves of the SET2 cell recipient mice described in panel A. The P value was determined using the log-rank Mantel-Cox test (∗P < .05). (D) Western blots showing the pharmacodynamics of BCL-xL degradation by DT2216 and densitometric quantification of BCL-xL in vehicle and DT2216 groups in a second cohort of mice (n = 3 mice per group). Starting at day 28 after SET2 cell transplantation, the mice were administered 2 doses, 4 days apart, of vehicle or DT2216 (15 mg/kg). α-Tubulin was used as the loading control for the western blot.